Generic drug manufacturers Lifestar Pharma and Chartwell Pharmaceuticals may owe refunds to 340B covered entities for overcharges on drugs purchased from the companies in the fourth quarter of 2022, according to recent notices posted on the U.S. Health Resources and Services Administration website.
Lifestar Pharma, based in Mahwah, N.J., “completed a minor restatement of government pricing values,” that impacted 340B pricing on certain drugs purchased between Oct. 1 and Nov. 17 of last year, according to a Lifestar notice dated April 17 and posted by HRSA late last week. The potential overcharges affect four NDCs.
Generic drug manufacturers Lifestar Pharma and Chartwell Pharmaceuticals may owe refunds to 340B covered entities for overcharges on drugs purchased from the companies in the fourth quarter of 2022, according to recent notices posted on the U.S. Health Resources and […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
